Tag Archives: Chief Medical Officer

Business, Finance, Occupation & Industry

GE Healthcare Launches its First "Next-Generation" Sequencing Assay

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

GE Healthcare Launches its First “Next-Generation” Sequencing Assay

ALISO VIEJO, Calif.–(BUSINESS WIRE)– GE Healthcare announced today that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials. This assay will empower researchers to perform prospective and retrospective analysis to better understand which patients will respond to particular therapies, to help stratify patient populations for ongoing clinical trials, and to aid early research efforts.

The assay is the first next-generation sequencing assay launched by GE Healthcare since its acquisition of SeqWright, Inc., a research laboratory offering nucleic acid sequencing and other genomic services. The acquisition added complementary genomics capabilities to Clarient, providing a platform for Clarient to expand its clinical diagnostic offerings to include next generation sequencing.

“Today, pharmaceutical companies are focusing on particular key drivers of cancer to develop targeted therapies,” said Kenneth J. Bloom, MD, Chief Medical Officer, Clarient Diagnostic Services, Inc. “By providing an assay limited to the most relevant and actionable genes in drug development today, we hope to further our mission of bringing clarity to a complex disease and aiding the biopharmaceutical industry in their clinical research endeavors. Additionally, because genomic sequencing procedures are important technologies for GE Healthcare’s medical diagnostics business, availability of this assay allows us to offer a substantially wider range of services to the biopharmaceutical, diagnostic and research industries and eventually to health care providers and patients.”

This new offering will further enable GE Healthcare’s current collaborations with pharmaceutical companies focused on biomarker research. The assay will target the 26 most common oncogenes and tumor suppressor genes, selected for their implication in prevalent solid tumor indications such as lung cancer, breast cancer, colon cancer and melanoma. The assay will be performed at Clarient’s CLIA-certified facility, where reflex and adjunct testing can be performed as necessary.

GE Healthcare, through its Clarient business, currently offers a number of comprehensive clinical and research assays focused on the most common mutations in solid tumor indications as well as leukemia and lymphomas. With this offering, GE Healthcare continues to refine its strategy and focus on the most actionable genes within oncology. Today’s announcement also reinforces the Company’s commitment to cancer and reflects its current integrated portfolio and GE Healthcare’s $1B R&D investment to advance oncology solutions by 2016.

“When GE Healthcare acquired SeqWright last year, one goal was to add incremental value to our existing pharmaceutical and biotechnology partnerships throughout their drug development and companion diagnostic development efforts,” said Carrie Eglinton-Manner, CEO, Clarient. “Availability …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combinat

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

-Two Phase 2 studies to evaluate once-daily combination of Vertex’s investigational nucleotide analogue VX-135 and BMS’ investigational NS5A replication complex inhibitor daclatasvir-

-Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013-

-Study in people with genotypes 1, 2 and 3 hepatitis C, including people with cirrhosis, planned for second half of 2013-

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (NAS: VRTX) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company (NYS: BMY) to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Bristol-Myers Squibb’s NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in treatment-naïve people with genotype 1 HCV infection planned for the second quarter of 2013. Vertex plans to begin a subsequent study in treatment-naïve people infected with genotype 1, 2 or 3 HCV, including those with cirrhosis, in the second half of 2013, pending data from the initial study.

“With more than 170 million people infected worldwide, there is a critical need for new hepatitis C medicines that can offer people simpler and more tolerable treatment regimens that provide high cure rates,” said Robert Kauffman, M.D., Ph.D., Senior Vice President and Chief Medical Officer at Vertex. “These studies with daclatasvir will provide the first opportunity to evaluate VX-135 as part of all-oral regimens in people with multiple hepatitis C genotypes and in people with cirrhosis.”

Clinical Development Plans for VX-135 with Daclatasvir

Under the terms of the agreement, Vertex will conduct two Phase 2 studies of VX-135 in combination with daclatasvir. The first study will enroll approximately 20 non-cirrhotic, treatment-naïve people with chronic genotype 1 HCV infection and is expected to begin in the second quarter of 2013. In the second half of 2013, …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial

Study to investigate [ 123 I] NAV5001 SPECT imaging as a tool to evaluate dopamine transporters in the brain as start of program in Dementia with Lewy Bodies

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators at Molecular Neuroimaging, LLC (MNI) in New Haven, CT have enrolled the first subject in a clinical study to investigate the performance of [123I]NAV5001 in a SPECT imaging procedure in connection with Navidea’s program to evaluate NAV5001 in Dementia with Lewy Bodies (DLB).

“This collaborative investigator-initiated study is an important first step in recommencing a full clinical development program for NAV5001 since our in-licensing this candidate in late 2012,” said Dr. Mark Pykett, Navidea’s President and CEO. “Collaborations such as this are integral to Navidea’s strategy to efficiently and effectively advance the development of our promising radiopharmaceutical pipeline and representative of our focus of being a leader in the field of precision diagnostics.”

“The study is the first leg of our program to evaluate the utility of NAV5001 in DLB, the leading form of dementia after Alzheimer’s disease and an important potential indication for NAV5001 medically and commercially,” commented Cornelia Reininger, MD, PhD, Navidea’s Senior Vice President and Chief Medical Officer. “During 2013, we look forward to following this study with the initiation of a Company-sponsored Phase 2b study of NAV5001 in DLB as well as the anticipated start of the Company’s pivotal parallel Phase 3 registration studies of NAV5001 as an aid in the differential diagnosis of Parkinsonian syndromes.”

The goal of this single center, open-label, investigator-initiated study will be to assess the distribution, safety and tolerability of NAV5001 as an agent to evaluate the integrity of the dopamine transporters in the brain, using healthy volunteers. NAV5001 is an investigational radiopharmaceutical imaging agent being developed as an aid in the differential diagnosis of Parkinsonian syndromes, including Parkinson’s disease (PD) and other movement disorders, as well as Dementia with Lewy Bodies (DLB). Danna Jennings, MD, Clinical Research Director at MNI will lead the investigator-initiated clinical study.

About NAV5001

[123I]NAV5001 is a patented, novel, small molecule radiopharmaceutical used with single photon emission computed tomography (SPECT) imaging to identify the status of specific regions in the brains of patients suspected of having Parkinson’s disease. The …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Sub

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)


– Study to evaluate NAV4694 in monitoring progression of MCI to Alzheimer’s Disease –

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography (PET) imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment (MCI). The study is designed to investigate whether NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with MCI who progress to Alzheimer’s disease (AD) from those who do not. Enrollment is currently planned at approximately five sites throughout the U.S. The first patient has been enrolled by the Alzheimer’s Disease Center at Quincy Medical Center in Quincy, MA.

“We are pleased to participate in this important clinical study of NAV4694 aimed at evaluating a patient population in whom dementia is just emerging and for whom it is believed the best prospects for therapeutic intervention will exist,” said Dr. Anil K. Nair, MD, Chief of Neurology and Head of the Alzheimer’s Disease Center at Quincy Medical Center in Quincy, MA. “Clinical trial results to date indicate that NAV4694 shows favorable sensitivity and specificity in detecting β-amyloid while exhibiting low white-matter uptake for clearer images that may assist in differential diagnoses associated with MCI. If AD could be diagnosed at an earlier stage, before clinical dementia has fully developed, the potential for successful intervention with current and future treatments could be improved considerably.”

“As the dementia field moves to earlier evaluation and treatment of cognitive impairment, it is of increasing importance to have diagnostic agents that can accurately detect the underlying cause. To our knowledge this is the first prospective, multi-center study to evaluate a radiopharmaceutical β-amyloid agent solely in subjects with MCI, an area of extreme importance as Alzheimer’s disease is expected to impact as many as 14 million Americans by 2050,” commented Cornelia Reininger, MD, PhD, Navidea’s Senior Vice President and Chief Medical Officer. “The outcome of this trial may enable accurate differentiation of MCI subjects who are at risk of developing Alzheimer’s disease from those who are not before the disease has reached more advanced stages that can impair activities of daily living. Our ultimate goal is …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Verastem Reports Year-End 2012 Financial Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Verastem Reports Year-End 2012 Financial Results

–Advancing Clinical Development Programs Targeting Cancer Stem Cells through FAK and PI3K/mTOR Inhibition–

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Verastem, Inc., (NAS: VSTM) , a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported financial results for the year ended December 31, 2012, and also commented on corporate accomplishments and plans.

“Verastem achieved important milestones in our mission to bring new therapies targeting cancer stem cells to patients during 2012,” said Christoph Westphal, M.D., Ph.D., Chairman and Chief Executive Officer of Verastem. “We have built a strong foundation to translate the groundbreaking work of Bob Weinberg to clinical practice. In addition to our ongoing combination study in ovarian cancer, we are on track to initiate a potentially pivotal study of VS-6063 in mesothelioma.”

“The Phase 1/1b trial of lead FAK inhibitor, VS-6063, in combination with paclitaxel for patients with ovarian cancer is open and enrolling at all sites,” said Dr. Joanna Horobin, Chief Medical Officer of Verastem. “In addition to the potential benefit in ovarian cancer, the results from this trial may allow us to expand into additional tumor types where the combined use of a cancer stem cell inhibitor with the commonly used paclitaxel may be a more effective treatment.”

Verastem plans to initiate a potentially pivotal trial of VS-6063 in mesothelioma midyear 2013. Mesothelioma is a highly aggressive disease with an approximate median overall survival of just 12 months from diagnosis of advanced disease. Verastem studies have demonstrated that FAK inhibitors strongly reduce cancer stem cells in preclinical models of mesothelioma. In addition, in a recent third party Phase 1 clinical study of a FAK inhibitor, the median progression-free survival for patients with recurrent mesothelioma was tripled as compared to the reported historical median time to progression on placebo.

“We will continue to expand our FAK franchise in 2013 with a Phase 1 trial of VS-4718, our second FAK inhibitor, in advanced cancers, which is expected to commence in the first half of this year,” continued Dr. Horobin. “In addition, we are conducting IND-enabling studies to support the entry of our PI3K/mTOR inhibitor, VS-5584, into a Phase 1 trial during the second half of the year.”

“During 2012, Verastem secured firm financial footing with our initial public offering and accelerated our programs targeting cancer stem cells through translational research …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

California United Bank CEO Forums Continue to Assist Southern California Businesses

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

California United Bank CEO Forums Continue to Assist Southern California Businesses

Latest installment discusses how companies can prepare for Health Care Reform

TORRANCE, Calif.–(BUSINESS WIRE)– California United Bank (CUB), a subsidiary of CU Bancorp (NAS: CUNB) , continued its CEO Forum series on Thursday, February 28th, by presenting “Health Care Reform – it’s the Law” to business owners and executives at the Miyako Hotel in Torrance.

“We are entering uncharted waters in terms of Health Care Reform‘s impact on businesses,” noted CUB Senior Vice President, Kim Defenderfer. “We want to make sure our clients, as well as the broader business community, are prepared and have all the resources that they need to reduce risks and costs.”

The event consisted of presentations by Lisa M. Santora, MD, MPH, Chief Medical Officer at Beach Cities Health District, and Jacqueline S. Roth, Health Care Specialist at Bolton & Company, as well as breakout sessions where the CEOs had the opportunity to share best practices.

“It was an enlightening forum,” commented Bill Frank, CFO of Dion & Sons. “Hearing from the experts, as well as being able to share ideas with businesspeople in similar situations, was invaluable.”

About CU Bancorp and California United Bank

CU Bancorp is the parent of California United Bank, which was founded in 2005 and is the largest independent bank headquartered in the San Fernando Valley. California United Bank provides a full range of financial services, including credit and deposit products, cash management, and internet banking to businesses, non-profits, entrepreneurs, professionals and investors throughout Southern California from offices in the San Fernando Valley, the Santa Clarita Valley, the Conejo Valley, Simi Valley, Los Angeles, South Bay, and Orange County. To view CU Bancorp’s most recent financial information, please visit the Investor Relations section of the Company’s Web site. Information on products and services may be obtained by calling 818-257-7700 or visiting the Bank’s Web site at www.cunb.com.

Torrey Pines Marketing
Troy Morrison, 619-723-8232

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article California United Bank CEO Forums Continue to Assist Southern California Businesses …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

InSite Vision Announces Positive Phase 3 Results for BromSite™ (ISV-303) for the Reduction of Inflam

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

InSite Vision Announces Positive Phase 3 Results for BromSite ™ (ISV-303) for the Reduction of Inflammation and Pain after Cataract Surgery

BromSite Demonstrates Statistical Significance Over Vehicle

ALAMEDA, Calif.–(BUSINESS WIRE)– InSite Vision Incorporated (OTCBB:INSV) today announced top-line results from its recently completed Phase 3 clinical trial of BromSite™ (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite achieved statistically significant superiority compared to vehicle in alleviating ocular pain and inflammation among patients following cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite® drug delivery technology.

“The results of our Phase 3 clinical study verify the efficacy of BromSite in providing relief of pain and inflammation after cataract surgery at a lower drug concentration than the current market leader and reinforce our earlier clinical findings,” said Kamran Hosseini, M.D., Ph.D., Chief Medical Officer of InSite Vision. “We plan to rapidly initiate the second Phase 3 trial of BromSite in order to be prepared to file for regulatory approvals in both the United States and Europe as soon as possible after the completion of that trial.”

The BromSite Phase 3 clinical trial enrolled 268 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite against the DuraSite vehicle alone. Patients were randomized and then dosed twice-a-day beginning the day before surgery and continuing the day of surgery and for 14 days post-surgery. The primary study endpoint was the reduction of inflammation after surgery and BromSite achieved statistically significant superiority compared to vehicle (p<0.001). A secondary endpoint was reduction in pain and BromSite achieved statistically significant superiority compared to vehicle (p<0.001). BromSite was well tolerated, with no safety concerns or drug-related serious adverse events reported. Pharm-Olam International served as the contract research organization managing the BromSite study on behalf of InSite Vision.

Cataract surgery is the most frequently performed ocular surgery in the United States, with more than three million procedures annually. Typically, anti-inflammatory eye drops are prescribed to reduce pain and inflammation both before and after surgery. Anti-inflammatory eye drops are also administered as prophylaxis against cystoid macular edema, or CME. CME is a relatively rare, but extremely serious, adverse event that can result from ocular surgery and lead to blindness. Many physicians believe that a higher penetration of bromfenac into the ocular tissues may reduce the risk of CME. In a Phase 2 clinical study evaluating pharmacokinetics, BromSite achieved more than twice the eye tissue penetration of Bromday™ (bromfenac …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeut

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

– ALN-TTRsc is Company’s First Subcutaneously Delivered RNAi Therapeutic to Enter Clinical Trials –

– Data from Trial Expected Mid-2013 –

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR). ATTR is caused by mutations in the TTR gene which cause abnormal amyloid protein deposits to accumulate in various tissues including peripheral nerves and heart, resulting in neuropathy and/or cardiomyopathy. ATTR represents a major unmet medical need with significant morbidity and mortality; familial amyloidotic polyneuropathy (FAP) affects approximately 10,000 people worldwide and familial amyloidotic cardiomyopathy (FAC) affects at least 40,000 people worldwide. ALN-TTRsc, which is being developed for the treatment of FAC, is a subcutaneously administered RNAi therapeutic that comprises an siRNA conjugated to a GalNAc ligand that enables receptor-mediated delivery to the liver. ALN-TTRsc is the first GalNAc-siRNA and the first subcutaneously delivered, systemic RNAi therapeutic to enter clinical development stages.

“RNAi therapeutics hold great promise for the treatment of ATTR since they have demonstrated rapid, potent, and durable knockdown of TTR, the disease-causing protein. We are advancing what we believe to be the industry leading effort in ATTR; this includes ALN-TTRsc for the treatment of FAC and ALN-TTR02 for the treatment of FAP which is currently enrolling patients in a Phase II trial,” said Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam. “The start of this Phase I trial with ALN-TTRsc represents the first for an RNAi therapeutic that utilizes our proprietary GalNAc conjugate delivery platform. It also marks the first subcutaneously delivered, systemic RNAi therapeutic for the industry. We look forward to the continued advancement of ALN-TTRsc for the treatment of FAC.”

The Phase I trial of ALN-TTRsc is being conducted in the U.K. as a randomized, double-blind, placebo-controlled, single- and multi-dose, dose-escalation study, enrolling up to 40 healthy volunteer subjects. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of subcutaneously administered ALN-TTRsc. Secondary objectives include assessment of clinical …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Medical Aesthetics Veteran Frederick Beddingfield, III, MD, PhD Appointed New Chief Medical Officer

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Medical Aesthetics Veteran Frederick Beddingfield, III, MD, PhD Appointed New Chief Medical Officer of KYTHERA Biopharmaceuticals

LOS ANGELES–(BUSINESS WIRE)– KYTHERA Biopharmaceuticals, Inc. (NAS: KYTH) , a biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the appointment of Frederick Beddingfield, III, MD, PhD as Chief Medical Officer. Dr. Beddingfield is a board-certified dermatologist who brings exceptional pharmaceutical and medical device development experience to KYTHERA. He joins the company from Allergan, Inc., where he worked in an executive capacity across the entire aesthetics portfolio including Botox® Cosmetic, Juvederm® and Latisse®. He most recently held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics. In addition, he has substantial experience across medical dermatology including acne, rosacea, hair growth and scar prevention.

“Dr. Beddingfield is recognized as one of the leaders in medical aesthetic innovation and will immediately become an integral member of KYTHERA‘s executive team,” said Keith Leonard, KYTHERA‘s President and CEO. “His depth and breadth of experience will undoubtedly help further our mission to bring great science, clinical rigor and real innovation to the growing area of medical aesthetics.”

Dr. Beddingfield will lead all clinical research and development, including strategy, operations, statistics, data management, medical writing, regulatory and quality.

“KYTHERA‘s spirit of innovation and their unequaled commitment to developing safe and novel aesthetic treatments is what attracted me to the company,” said Dr. Beddingfield. “I look forward to building on the research success of ATX-101 and the opportunity to advance aesthetic medicine beyond the current treatment categories.”

An innovative physician-scientist, Dr. Beddingfield has experience working on premier products in the aesthetics industry, including Allergan’s Botox Cosmetic, Juvederm and Latisse, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield served in several roles, including Chief Medical Officer, Allergan Medical, and Global Team Leader of several brands, including Botox Facial Aesthetics, Botox Hyperhidrosis, Dermal Fillers and Botox Spasticity. Earlier in his career, he held a full-time faculty position at UCLA David Geffen School of Medicine, Division of Dermatology, where he continues to maintain an academic appointment as Assistant Clinical Professor of Medicine. Dr. Beddingfield earned an MD degree with honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.

Effective March 23, Dr. Beddingfield succeeds Patricia Walker, MD, PhD, who joined KYTHERA in 2007 as Chief Medical Officer. Prior to joining KYTHERA, Dr. Beddingfield worked under Dr. Walker’s tutelage for three years …read more
Source: FULL ARTICLE at DailyFinance

Health

Antimicrobial Resistance Poses Grave Threat

Leave a comment

The topic of antimicrobial resistance needs to be addressed – in 20 years it could result in death following minor surgery – according to the annual report by the Chief Medical Officer in the UK. The warning comes as a part of the report giving an extensive overview of the antimicrobial resistance threat and infectious diseases… …read more
Source: FULL ARTICLE at Medical News Today

Business, Finance, Occupation & Industry

Virginia Dept. of Behavioral Health &amp; Developmental Services selects Siemens Soarian

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Virginia Dept. of Behavioral Health & Developmental Services selects Siemens Soarian

  • Enterprise-wide delivery includes using Soarian® Clinicals and Financials to support complex behavioral health needs, MobileMD® HIE to help providers securely share behavioral health records, and Healthcare Intelligence to enable population health management
  • Embedded workflow technology drives timely, interdisciplinary treatment plans

MALVERN, Pa.–(BUSINESS WIRE)– Today, Siemens Healthcare announced that the company will provide the Soarian enterprise electronic health record (EHR) to the Virginia Department of Behavioral Health and Developmental Services (DBHDS), Richmond, Va., a non-acute, specialty care provider. The purchase delivers Soarian functionality across 14 facilities, replacing a disparate array of healthcare IT solutions and semi-manual paper-centric processes for orders. The decision was based on Soarian’s adaptable, workflow-driven architecture; the ability for Siemens MobileMD Health Information Exchange (HIE) to help providers access mental health records, securely, among different care settings such as the hospital or their main practice locations; and by the potential to influence population health management with Healthcare Intelligence, a new solution from Siemens that collects both clinical and financial data as well as structured and unstructured data for analysis. As part of Agenda 2013, a two-year global initiative in the Siemens Healthcare Sector, the company is identifying new ways to address the unique needs of customers in a variety of settings.

“Soarian allows us to document and manage information in a way that can improve the safety and effectiveness of treatment,” said Jack Barber, MD, Chief Medical Officer. “Our providers appreciated the streamlined capabilities to not only view and document patient care but to manage a longitudinal interdisciplinary treatment plan across departments and settings.”

The Virginia DBHDS purchased a comprehensive suite of Soarian Clinicals, Soarian Financials, Healthcare Intelligence, Siemens Pharmacy and Med Administration Check™, and Siemens MobileMD HIE. Pilot implementations are planned for mid 2013 at three sites: Western State Hospital and Commonwealth Center for Children & Adolescents in Staunton, and Eastern State Hospital in Williamsburg, Va. Siemens has selected Quammen Healthcare Consultants, Murfreesboro, Tenn., to lead the implementation efforts.

“Our clinical leadership and staff were closely involved throughout the entire vendor/product selection process,” said Russell Sarbora, CIO, Virginia DBHDS. “Siemens heard our need and responded in a manner that engendered confidence in both the company and its solution suite.”

Available to citizens statewide, …read more
Source: FULL ARTICLE at DailyFinance